TikTok is pulling back on an AI feature that added wildly inaccurate text summaries to videos from users like Charli D'Amelio ...

Charli D’Amelio stunned fans with her newest Instagram snaps, in which she wore a jaw-dropping backless dress. The attire not only accentuated her beauty but also dived into risky territory via a ...

So what does this Wall Street analyst like about Lilly? Yesterday, Eli Lilly announced it will spend $7 billion to acquire privately held Kelonia Therapeutics and its KLN-1010 CAR-T gene therapy drug ...

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

Charli xcx is heading to the 2026 Met Gala! The singer and living legend stepped out of her hotel and made her way to the red carpet wearing a beautiful black Saint Laurent gown by Anthony Vaccarello ...

Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...

Eli Lilly LLY0.87%increase; green up pointing triangle continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer ...

Novo Nordisk's Wegovy pill has created another boom in the GLP-1 drug market. Eli Lilly recently introduced its Foundayo pill for weight loss, three months after the launch of its rival's drug. The ...

Eli Lilly LLY is set to release its first-quarter 2026 earnings report on April 30. Here’s Morningstar’s take on what to look for in Lilly’s earnings and the outlook for its stock. With its 3-star ...

The product in question is Eli Lilly's Foundayo, the company's first pill approved by the U.S. Food and Drug Administration (FDA) for weight loss. Hopes were high for the drug, particularly given the ...

Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the Big Pharma team up with Profluent to develop AI-designed recombinases to address diseases with severe unmet needs.

April 28 (Reuters) - AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly (LLY.N), opens new tab worth up ‌to $2.25 billion to develop ...